查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1671096

全球血友病 A 治療市場：市場規模、佔有率、趨勢、行業分析（依治療類型、治療方法、通路和地區）、未來預測（2025-2034年）

Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Therapy Type, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，全球血友病 A 治療市場預計到2034年將達到 198.6億美元。本研究報告對當前市場動態提供了詳細的見解，並對未來市場成長進行了分析。

血友病 A 治療是指透過醫療介入來管理和治療血友病 A。這種遺傳性疾病會導致血液凝結因子 VIII 不足，導致血液難以凝結並增加過度出血的風險。血友病 A 的主要治療方法是透過重組或血漿衍生的凝血因子替代療法來補充缺失的凝血因子。

血友病 A 治療市場受到基因療法、延長半衰期的因子 VIII 藥物以及非因子替代療法（如 emicizumab）等治療方案的進步所推動。人們對血友病及其管理的認識不斷提高以及醫療保健投資不斷增加，改善治療的機會，尤其是在新興市場。

存在開發創新療法的機會，這些療法可以解決遺傳根本原因，並透過皮下注射等侵入性較小的治療方法提高患者的依從性。一個顯著的趨勢是開發延長半衰期的VIII 因子製劑，可以減少給藥頻率。此外，對非因子替代產品和基因編輯技術等創新治療方法的大量投資塑造市場格局。

血友病 A 治療市場：概論

根據治療類型，預防性治療（可預防出血發作並改善患者的生活品質）佔血友病 A 治療市場的最大佔有率。它日益被提倡為長期治療選擇，尤其是對於年輕患者。

根據治療類型，第VIII 因子製劑廣泛用於按需治療和預防，其中重組療法和血漿衍生的第VIII 因子產品佔據市場主導地位。基因治療和單株抗體是成長最快的領域，並可能提供長期解決方案。

醫院藥局在急性和緊急護理中發揮關鍵作用，是主要的通路。專業藥房經歷最快的成長，特別是在基因療法和單株抗體等先進療法領域。

北美佔據最大的市場佔有率，這得益於完善的醫療保健基礎設施和創新療法的高採用率。由於醫療保健覆蓋面的擴大、患者意識的增強以及對新興經濟體的投資不斷增加，亞太地區經歷快速成長。

目錄

第1章 簡介

第2章 執行摘要

第3章 分析方法

第4章 血友病 A 治療市場洞察

  • 市場概況
  • 血友病 A 治療的市場動態
    • 驅動因素和機會
      • 基因治療的進展
      • 採用半衰期延長產品
      • 非因子替代療法的興起
    • 阻礙因素和挑戰
      • 醫療費用上漲
  • PESTLE 分析
  • 血友病 A 治療市場趨勢
  • 價值鏈分析
  • COVID-19 影響分析

第5章 全球血友病 A 治療市場（依治療類型）

  • 主要調查結果
  • 簡介
  • 按需
  • 治療
  • 預防

第6章 全球血友病 A 治療市場（依治療類型）

  • 主要調查結果
  • 簡介
  • 因子替代療法
  • 去氨加壓素纖維蛋白密封劑
  • 基因治療/單株抗體

第7章 全球血友病 A 治療市場（依通路）

  • 主要調查結果
  • 簡介
  • 醫院藥房
  • 專業藥房

第8章 全球血友病 A 治療市場（依地區）

  • 主要調查結果
  • 簡介
    • 依地區對血友病 A 治療市場的評估（2020年至2034年）
  • 北美洲
    • 北美：依治療類型（2020-2034年）
    • 北美：依治療類型（2020-2034年）
    • 北美：依通路（2020-2034年）
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：依治療類型（2020-2034年）
    • 歐洲：依治療類型（2020-2034年）
    • 歐洲：依通路（2020-2034年）
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 亞太地區：依治療類型（2020-2034年）
    • 亞太地區：依治療類型（2020-2034年）
    • 亞太地區：依通路（2020-2034年）
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東和非洲
    • 中東和非洲：依治療類型（2020-2034年）
    • 中東和非洲：依治療類型（2020-2034年）
    • 中東和非洲：依通路（2020-2034年）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲：依治療類型（2020-2034年）
    • 拉丁美洲：依治療類型（2020-2034年）
    • 拉丁美洲：依通路（2020-2034年）
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家

第9章 競爭格局

  • 擴張與收購分析
    • 擴張
    • 收購
  • 夥伴關係/協作/協議/公開

第10章 公司簡介

  • CSL Behring
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Sanofi（through its acquisition of Bioverativ）
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Grifols S.A.
  • BioMarin Pharmaceutical Inc.
  • Spark Therapeutics（a subsidiary of Roche）
  • Aptevo Therapeutics
  • Kedrion Biopharma
  • Sangamo Therapeutics
  • uniQure N.V.
Product Code: PM1107

The global hemophilia A treatment market size is expected to reach USD 19.86 billion by 2034, according to a new study by Polaris Market Research. The report "Hemophilia A Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (On-Demand, Cure, and Prophylaxis), Therapy Type, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hemophilia A treatment refers to the medical interventions used to manage and treat hemophilia A. In this genetic disorder, the blood lacks sufficient clotting factor VIII, leading to difficulty in blood clotting and an increased risk of excessive bleeding. The primary treatment for Hemophilia A involves replacing the missing clotting factor through factor replacement therapy, which can be either recombinant or plasma-derived.

The hemophilia A treatment market is driven by advancements in therapeutic options, including gene therapy, extended half-life factor VIII products, and non-factor replacement therapies like emicizumab. Growing awareness about hemophilia and its management, along with increasing healthcare investments, is enhancing access to treatments, particularly in emerging markets.

Opportunities exist in developing innovative therapies that address the genetic root causes and improve patient compliance through less invasive treatment options such as subcutaneous injections. A notable trend is the development of extended half-life factor VIII products, offering reduced dosing frequency. Additionally, significant investments in innovative therapies, including non-factor replacement products and gene-editing technologies, are shaping the market landscape.

Hemophilia A Treatment Market Report Highlights

Based on treatment type, prophylaxis holds the largest share in the hemophilia A treatment market due to its ability to prevent bleeding episodes and improve patient quality of life. It is increasingly favored for long-term management, particularly among younger patients.

By therapy type, the factor replacement therapy segment dominates the market, with recombinant and plasma-derived factor VIII products being widely used for on-demand treatment and prophylaxis. Gene therapy & monoclonal antibodies is the fastest-growing segment, offering potential long-term solutions.

Hospital pharmacies are the dominant distribution channel due to their critical role in acute care and emergency treatment. Specialty pharmacies are registering the fastest growth, particularly for advanced therapies like gene therapy and monoclonal antibodies.

North America holds the largest market share, driven by a well-established healthcare infrastructure and high adoption of innovative therapies. Asia Pacific is the fastest-growing region, fueled by expanding healthcare access, rising patient awareness, and increasing investments in emerging economies.

Polaris Market Research has segmented the hemophilia A treatment market report on the basis of treatment type, therapy type, distribution channnel, and region:

By Treatment Type Outlook (Revenue - USD Billion, 2020-2034)

  • On-Demand
  • Cure
  • Prophylaxis

By Therapy Type Outlook (Revenue - USD Billion, 2020-2034)

  • Factor Replacement Therapy
  • Desmopressin & Fibrin Sealants
  • Gene Therapy & Monoclonal Antibodies

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

  • Hospital Pharmacies
  • Specialty Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global Hemophilia A Treatment Market Insights

  • 4.1. Hemophilia A Treatment Market - Market Snapshot
  • 4.2. Hemophilia A Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in Gene Therapy
      • 4.2.1.2. Adoption of Extended Half-Life Products
      • 4.2.1.3. Rise of Non-Factor Replacement Therapies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Hemophilia A Treatment Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Hemophilia A Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. On-Demand
    • 5.3.1. Global Hemophilia A Treatment Market, by On-Demand, by Region, 2020-2034 (USD Billion)
  • 5.4. Cure
    • 5.4.1. Global Hemophilia A Treatment Market, by Cure, by Region, 2020-2034 (USD Billion)
  • 5.5. Prophylaxis
    • 5.5.1. Global Hemophilia A Treatment Market, by Prophylaxis, by Region, 2020-2034 (USD Billion)

6. Global Hemophilia A Treatment Market, by Therapy Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • 6.3. Factor Replacement Therapy
    • 6.3.1. Global Hemophilia A Treatment Market, by Factor Replacement Therapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Desmopressin & Fibrin Sealants
    • 6.4.1. Global Hemophilia A Treatment Market, by Desmopressin & Fibrin Sealants, by Region, 2020-2034 (USD Billion)
  • 6.5. Gene Therapy & Monoclonal Antibodies
    • 6.5.1. Global Hemophilia A Treatment Market, by Gene Therapy & Monoclonal Antibodies, by Region, 2020-2034 (USD Billion)

7. Global Hemophilia A Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Hemophilia A Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Specialty Pharmacies
    • 7.4.1. Global Hemophilia A Treatment Market, by Specialty Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Hemophilia A Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Hemophilia A Treatment Market Assessment, b y Geography, 2020-2034 (USD Billion)
  • 8.3. Hemophilia A Treatment Market - North America
    • 8.3.1. North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Hemophilia A Treatment Market - US
      • 8.3.4.1. US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.4.3. US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Hemophilia A Treatment Market - Canada
      • 8.3.5.1. Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Hemophilia A Treatment Market - Europe
    • 8.4.1. Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Hemophilia A Treatment Market - UK
      • 8.4.4.1. UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Hemophilia A Treatment Market - France
      • 8.4.5.1. France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Hemophilia A Treatment Market - Germany
      • 8.4.6.1. Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Hemophilia A Treatment Market - Italy
      • 8.4.7.1. Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Hemophilia A Treatment Market - Spain
      • 8.4.8.1. Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Hemophilia A Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Hemophilia A Treatment Market - Russia
      • 8.4.10.1. Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Hemophilia A Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Hemophilia A Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Hemophilia A Treatment Market - China
      • 8.5.4.1. China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Hemophilia A Treatment Market - India
      • 8.5.5.1. India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Hemophilia A Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Hemophilia A Treatment Market - Japan
      • 8.5.7.1. Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Hemophilia A Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Hemophilia A Treatment Market - South Korea
      • 8.5.9.1. South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Hemophilia A Treatment Market - Australia
      • 8.5.10.1. Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Hemophilia A Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Hemophilia A Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Hemophilia A Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Hemophilia A Treatment Market - UAE
      • 8.6.5.1. UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Hemophilia A Treatment Market - Israel
      • 8.6.6.1. Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Hemophilia A Treatment Market - South Africa
      • 8.6.7.1. South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Hemophilia A Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Hemophilia A Treatment Market - Latin America
    • 8.7.1. Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Hemophilia A Treatment Market - Mexico
      • 8.7.4.1. Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Hemophilia A Treatment Market - Brazil
      • 8.7.5.1. Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Hemophilia A Treatment Market - Argentina
      • 8.7.6.1. Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Hemophilia A Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. CSL Behring
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Takeda Pharmaceutical Company Limited
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bayer AG
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi (through its acquisition of Bioverativ)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann-La Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Octapharma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Grifols S.A.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. BioMarin Pharmaceutical Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Spark Therapeutics (a subsidiary of Roche)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Aptevo Therapeutics
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Kedrion Biopharma
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Sangamo Therapeutics
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. uniQure N.V.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables:

  • Table 1 Global Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 2 Global Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 3 Global Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 4 North America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 5 North America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 6 North America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 7 US: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 8 US : Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 9 US : Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 10 Canada: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 12 Canada: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 13 Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 15 Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 16 UK: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 17 UK: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 18 UK: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 19 France: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 20 France: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 21 France: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 22 Germany: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 24 Germany: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 25 Italy: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 27 Italy: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 28 Spain: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 30 Spain: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 34 Russia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 36 Russia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 43 China: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 44 China: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 45 China: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 46 India: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 47 India: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 48 India: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 52 Japan: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 54 Japan: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 58 South Korea: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 60 South Korea: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 61 Australia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 63 Australia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 73 UAE: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 75 UAE: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 76 Israel: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 78 Israel: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 79 South Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 81 South Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 85 Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 87 Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 88 Mexico: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 90 Mexico: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 91 Brazil: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 93 Brazil: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 94 Argentina: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 96 Argentina: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Hemophilia A Treatment Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Hemophilia A Treatment Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Hemophilia A Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Hemophilia A Treatment Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Hemophilia A Treatment Market, by Treatment Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy Type
  • Figure 9. Global Hemophilia A Treatment Market, by Therapy Type, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Hemophilia A Treatment Market, by Distribution Channel, 2024 & 2034 (USD Billion)